Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Chemotherapy Induction Followed by Chemoradiotherapy for Esophageal Cancer
NCT07306663Phase 3Active, not recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Jun 2021
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Started Jun 2021; status: active, not recruiting.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07306663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07306663.